P654: Monitoring of drug concentrations to predict remission under ustekinumab induction therapy in Crohn's disease patients
ECCO '19 Copenhagen
2019
P655: Microencapsulated Sodium Butyrate significantly modifies the microbiota in patients with inflammatory bowel disease mimicking prebiotic activity and proving effects on the treatment of the disease
ECCO '19 Copenhagen
2019
P656: Malnutrition rates are highest in pre-surgical Crohn’s disease when compared with active CD, CD in remission and UC in remission
ECCO '19 Copenhagen
2019
P657: Backwash ileitis not influences the risk of the pouchitis, but can increase the risk of the pouch dysplasia
ECCO '19 Copenhagen
2019
P658: Efficacy and safety of thalidomide in adults with refractory Crohn’s disease to maintain clinical remission: a retrospective cohort study
ECCO '19 Copenhagen
2019
P659: Efficacy of switching from infliximab to golimumab in ulcerative colitis patients on deep remission
ECCO '19 Copenhagen
2019
P660: Stability of serum concentrations of infliximab and adalimumab across pregnancy in IBD
ECCO '19 Copenhagen
2019
P661: Early histological improvement demonstrated with oral ozanimod in patients with moderately to severely active Crohn’s disease in the STEPSTONE trial
ECCO '19 Copenhagen
2019
P662: Remission to vedolizumab is not higher in TNF-naïve compared with TNF-pre-treated patients with Crohn’s disease
ECCO '19 Copenhagen
2019
P663: The effect of vitamin D deficiency, and its correction, on healthcare utilisation among patients with inflammatory bowel disease (IBD)
ECCO '19 Copenhagen
2019
P664: SB5 and reference adalimumab show cross-immunogenicity in patients with inflammatory bowel disease or rheumatoid arthritis
ECCO '19 Copenhagen
2019
P665: 1-Year clinical and endoscopic follow-up of vedolizumab therapy in refractory PIBD patients
ECCO '19 Copenhagen
2019
P666: Safety of combination biologic and immunosuppressive therapy post-orthotopic liver transplantation in patients with inflammatory bowel disease: a systematic review
ECCO '19 Copenhagen
2019
P667: Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates in 72 patients, a report from a district general hospital
ECCO '19 Copenhagen
2019
P668: Ustekinumab induction effectiveness in Crohn’s disease in a real-life cohort
ECCO '19 Copenhagen
2019
P669: Transmural healing is associated with higher infliximab trough levels in Crohn’s disease
ECCO '19 Copenhagen
2019
P670: Therapeutic efficacy and economic impact of half sulfasalazine therapy for refractory ulcerative colitis
ECCO '19 Copenhagen
2019
P671: Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands: a retrospective observational study
ECCO '19 Copenhagen
2019